Cumulative cognitive benefits and brain volume change with anti-amyloid therapies for Alzheimer's disease - PubMed
3 hours ago
- #Alzheimer's disease
- #cognitive decline
- #anti-amyloid therapy
- Study evaluates cumulative cognitive benefits of FDA-approved monoclonal antibodies (mABs) for Alzheimer's disease (AD).
- Compared to placebo, mABs showed 27.6% cognitive slowing and 5.52-month delay in progression over 19.5 months.
- Cognitive decline was measured using ADAS-Cog and CDR-SOB scales.
- mABs progressively attenuated cognitive decline, while AChEIs showed smaller effects with uncertainty.
- Amyloid reduction and cognitive decline rates stabilized over time.
- Whole brain volume (WBV) initially declined rapidly but slowed progressively.
- WBV decline was not linked to worsening cognition; instead, a 1 cm³ reduction correlated with a 0.0975-point CDR-SOB reduction.
- mAB therapy provided greater cognitive benefits than placebo and AChEIs in prodromal to mild AD.
- WBV reduction may reflect a treatment-related process rather than a harmful effect.